WO2005123141A3 - Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent - Google Patents

Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent Download PDF

Info

Publication number
WO2005123141A3
WO2005123141A3 PCT/US2005/020447 US2005020447W WO2005123141A3 WO 2005123141 A3 WO2005123141 A3 WO 2005123141A3 US 2005020447 W US2005020447 W US 2005020447W WO 2005123141 A3 WO2005123141 A3 WO 2005123141A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
product
elicitor
cancer
targeting agent
Prior art date
Application number
PCT/US2005/020447
Other languages
French (fr)
Other versions
WO2005123141A2 (en
Inventor
Jack A Roth
Guido Schumacher
Sunil Chada
Original Assignee
Univ Texas
Introgen Therapeutics Inc
Jack A Roth
Guido Schumacher
Sunil Chada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Introgen Therapeutics Inc, Jack A Roth, Guido Schumacher, Sunil Chada filed Critical Univ Texas
Priority to CA002570017A priority Critical patent/CA2570017A1/en
Priority to EP05785560A priority patent/EP1758615A2/en
Publication of WO2005123141A2 publication Critical patent/WO2005123141A2/en
Publication of WO2005123141A3 publication Critical patent/WO2005123141A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers in combination with ErbituxTM(cetuximab). Viral and non-viral gene delivery systems are disclosed.
PCT/US2005/020447 2004-06-11 2005-06-10 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent WO2005123141A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002570017A CA2570017A1 (en) 2004-06-11 2005-06-10 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
EP05785560A EP1758615A2 (en) 2004-06-11 2005-06-10 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57903604P 2004-06-11 2004-06-11
US60/579,036 2004-06-11

Publications (2)

Publication Number Publication Date
WO2005123141A2 WO2005123141A2 (en) 2005-12-29
WO2005123141A3 true WO2005123141A3 (en) 2006-05-11

Family

ID=35376964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/020447 WO2005123141A2 (en) 2004-06-11 2005-06-10 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent

Country Status (4)

Country Link
US (1) US20060052322A1 (en)
EP (1) EP1758615A2 (en)
CA (1) CA2570017A1 (en)
WO (1) WO2005123141A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
JP2007530588A (en) * 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Receptor coupling agent and therapeutic use thereof
WO2007127951A2 (en) * 2006-04-28 2007-11-08 The Board Of Regents Of The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
WO2008157358A1 (en) * 2007-06-15 2008-12-24 University Of Medicine And Dentistry Of New Jersey Methods for treating neoplasia and for identifying compositions useful in such therapy
JP5630769B2 (en) * 2008-04-11 2014-11-26 井戸川 雅史 Apoptosis inducer
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
CN103405785B (en) * 2013-08-15 2014-10-08 山西大学 Use of gene GADD45 beta in preparation of drug for treating bladder cancer
US9987416B2 (en) * 2015-01-09 2018-06-05 BioQuiddity Inc. Sterile assembled liquid medicament dosage control and delivery device
CN104906596A (en) * 2015-05-20 2015-09-16 山西大学 Application of p50 gene in preparation of bladder cancer fighting drug
CN110139656A (en) * 2016-08-05 2019-08-16 纽约州州立大学研究基金会 The Keratin 17 of biomarker as bladder cancer
US10994116B2 (en) 2018-06-30 2021-05-04 Bioq Pharma Incorporated Drug cartridge-based infusion pump
US11338082B2 (en) 2019-09-04 2022-05-24 BloQ Pharma, Inc. Variable rate dispenser with aseptic spike connector assembly

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHADA SUNIL ET AL: "Development of vaccines against self-antigens: the p53 paradigm.", CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT. MAR 2003, vol. 6, no. 2, March 2003 (2003-03-01), pages 169 - 173, XP009059831, ISSN: 1367-6733 *
NIKITINA E Y ET AL: "An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53.", GENE THERAPY. MAR 2002, vol. 9, no. 5, March 2002 (2002-03-01), pages 345 - 352, XP009059830, ISSN: 0969-7128 *
SCHUMACHER G ET AL: "An adenovirus vector expressing wildtype p53 (Ad-p53) upregulates the EDF receptor and enhances growth inhibition of human breast cancer cell line when combined with anti-EGF receptor mAb C225", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 39, March 1998 (1998-03-01), & 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; NEW ORLEANS, LOUISIANA, USA; MARCH 28-APRIL 1, 1998, pages 419, XP001208111, ISSN: 0197-016X *
SCHUMACHER G ET AL: "Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 15 JAN 2001, vol. 91, no. 2, 15 January 2001 (2001-01-15), pages 159 - 166, XP009059829, ISSN: 0020-7136 *
XU LIANG ET AL: "Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes", MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 5, March 2002 (2002-03-01), pages 337 - 346, XP002362459, ISSN: 1535-7163 *

Also Published As

Publication number Publication date
WO2005123141A2 (en) 2005-12-29
US20060052322A1 (en) 2006-03-09
EP1758615A2 (en) 2007-03-07
CA2570017A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2005123141A3 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
WO2010065787A3 (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2008060510A3 (en) Zinc finger nuclease for targeting the human glucocorticoid receptor locus
WO2008103763A3 (en) Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
WO2010138806A8 (en) Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
WO2006066048A3 (en) Compositions for bacterial mediated gene silencing and methods of using same
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2007087451A3 (en) Compositions and methods for enhancing discriminatory rna interference
WO2007091269A3 (en) NOVEL TANDEM siRNAS
WO2006089001A3 (en) Lentiviral vectors and their use
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
UA89957C2 (en) Chimeric adenoviruses for use in cancer treatment
WO2008156702A3 (en) Bacteria mediated gene silencing
WO2008052770A3 (en) (base-)modified rna for increasing the expression of a protein
WO2010151671A3 (en) Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
MX342933B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein.
WO2011090741A3 (en) TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
WO2011085066A3 (en) Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
WO2010135695A3 (en) TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
WO2008073878A3 (en) Gene expression profiling of esophageal carcinomas
WO2010151674A3 (en) Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2011082281A3 (en) Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
WO2011017516A3 (en) Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2570017

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005785560

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005785560

Country of ref document: EP